EUCTR2006-001371-38-SI进行中（未招募）不适用
Cetuximab (Erbitux®), capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer: A phase II Pilot Study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age 18 to 80 if judged fit for surgery.
- •- WHO peformance status 0-1.
- •- Histologically proven rectal adenocarcinoma located below the peritoneum.
- •- T3-T4 or/and nodal involvement determined by rectal ultrasound or computed tomography (CT) or MRI.
- •- No distant metastases.
- •- Adequate haematological, cardiac, liver and renal function.
- •- Signed infomed consent.
- •- Appropriate measures for contraception for men and women, if applicable.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Prior radio- and/or chemotherapy.
- •- Others synchronous cancers.
- •- History of other malignant disease.
- •- Significant heart disease.
- •- Known hypersensitivity to biological drugs.
- •- Pregnant or lactating patient.
研究者
相似试验
进行中（未招募）
不适用
Cetuximab and cisplatin in addition to radiotherapy in the treatment of stage IIA-III carcinoma of the uterine cervix - a pilot phase II study.Stage IIA-III carcinoma of the uterine cervix.MedDRA version: 8.1Level: LLTClassification code 10041848Term: Squamous cell carcinoma of the cervixEUCTR2006-003759-19-SEDepartment of Gynecological Oncology, University Hospital, Örebro
进行中（未招募）
不适用
Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II TrialEUCTR2005-003911-63-DEniversity of Heidelberg, Frau I. Gürkan, Kaufmännische Direktorin46
进行中（未招募）
不适用
Cetuximab (ERBITUX) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck (''EXTREME'')EUCTR2004-001667-22-ITMERCK S.P.A.
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMERecurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 7.0Level: LLTClassification code 10025960EUCTR2004-001667-22-CZMerck KGaA420
进行中（未招募）
不适用
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck - EXTREMEMedDRA version: 7.0Level: LLTClassification code 10025960Recurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)EUCTR2004-001667-22-SEMerck KGaA420